Panagiotis Konstantinopoulos, MD
Enriched profileDirector, Mellen and Eisenson Family Center for BRCA and Related Genes; Director of Translational Research, Division of Gynecologic Oncology; Velma Eisenson Endowed Chair for Clinical and Translational Research, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute
Panagiotis Konstantinopoulos is Director, Mellen and Eisenson Family Center for BRCA and Related Genes; Director of Translational Research, Division of Gynecologic Oncology; Velma Eisenson Endowed Chair for Clinical and Translational Research, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 481 publications with 19,507 citations (h-index 66); ClinicalTrials.gov lists 12 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Panagiotis, MD, is Director, Mellen and Eisenson Family Center for BRCA and Related Genes at Dana-Farber Cancer Institute, Boston, MA. The public record shows 481 publications with 19,507 citations (h-index 66), centered on Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 13 companies, 2 NIH-funded awards (2020–2026).
- Most recent indexed publication: 2026 · Nature communications
- Top research focus: Ovarian cancer diagnosis and treatment
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 33 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 166.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Sponsor: Dana-Farber Cancer Institute
- Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Sponsor: Panagiotis Konstantinopoulos, MD, PhD
- ALPINE: Maintenance Letrozole/Abemaciclib
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 27 Aug 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20254 payments
- Gilead Sciences, Inc.Program year20252 payments
- AstraZeneca UK LimitedProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
54.8%Poly(ADP-Ribose) Polymerase Inhibitor54.8%Lynparza65%Zejula35%Part D<11 patientsNervous system
25.8%Phenothiazine25.8%Prochlorperazine Maleate100%Part D≥13 patientsMetabolism & gastrointestinal
19.4%Serotonin-3 Receptor Antagonist19.4%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
2 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
- Targeting Replication Stress and DNA Damage Response in Uterine Cancer
Dana-Farber Cancer Inst
FY2026$2,955,232P01CA269021
Congress activity
Updated 27 Aug 2026
57 congress contributions (2011–2026) across AACR, ASCO, ESMO per OpenAlex. The most recent:
- Abstract CT035: CTEP #10355 A phase 1 trial of DS-8201a and olaparib in HER2-expressing malignancies: Results from dose escalation
AACR Annual Meeting
AACR2026Co-author - A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512).
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial.
Nature communications
Clinical Trial2026 - Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.
Nature communications
Clinical Trial2025 - Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.
Journal of clinical oncology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/panagiotis-konstantinopoulos-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Panagiotis-A-Konstantinopoulos-2209328555
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/dana-farber-cancer-institute_panos-konstantinopoulos-md-phd-director-activity-7272762126534946816-T1_i
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
physicianresources.dana-farber.org/videos/panos-konstantinopoulos-md-phd-shares-results-of-a-phase-2-endometrial-cancer-study-at-2022-sgo
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicianresources.dana-farber.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- MD
University of Patras Medical School, Greece
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - PhD
University of Patras, Greece
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Master's degree in Clinical Investigation
Harvard Medical School and MIT Department of Health Sciences and Technology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Director
Mellen and Eisenson Family Center for BRCA and Related Genes, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Director of Translational Research
Division of Gynecologic Oncology, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Editorial Board Member
Journal of Clinical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopubs.org ↗
Awards & honors
honors on the public record- Top Doctor Award2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗
- Co-Chair
NRG Oncology Developmental Therapeutics (Translational Science) Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →physicianresources.dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute